ly2828360
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2011 (NCT01319929)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cannabinoid CB2 receptorAGONIST
CNR2 agonist
Phase 2 study in 2012 completed, no further studies recorded.
Chemistry & pharmacology
Loading structure…
SMILES
Cc1nc(N2CCN(C)CC2)c2nc(-c3ccccc3Cl)n(C3CCOCC3)c2n1- Mol. weight
- 426.95 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545033 ↗
- ChEMBLCHEMBL3139186 ↗
Also known as
- ly2828360
- ly2828360
- ly-2828360
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01319929 | Phase 2 | Mar 1, 2011 | Eli Lilly |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 1 | 1 | 1 | 2011 |
1 organizations
Page 1 / 1